Study of Vioxx and Radiation Therapy for Brainstem Glioma
Status:
Terminated
Trial end date:
2005-01-01
Target enrollment:
Participant gender:
Summary
It is of interest to determine whether COX-2 inhibitors given with radiation therapy can
prolong the progression-free survival in brain stem glioma. Diffuse pontine brainstem gliomas
are more common in children, but are also seen in adults. However, the use of commercially
available COX-2 inhibitors has not been evaluated in the pediatric population and the proper
dosing in pediatrics is unknown. Therefore a Phase I study will need to be conducted as a
first step. Rofecoxib is an FDA approved COX-2 inhibitor for use in adults. This phase I
study is designed to determine the maximum tolerated dose of Rofecoxib given concurrently
with standard radiation therapy for diffuse pontine brainstem glioma.